Home / Market News / $ONC
benzinga Corporate Catalyst Impact 55/100 ● positive

Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $420

Oct 7, 2026, 3:38 PM UTC · Primary ticker $ONC

Truist Securities has reiterated its 'Buy' rating for BeOne Medicines and slightly increased its price target from $418 to $420. This indicates continued analyst confidence in the company's prospects, though the modest price target adjustment suggests a limited immediate market impact.

Truist Securities analyst Gregory Renza has maintained a 'Buy' rating on BeOne Medicines (ONC) and raised the price target from $418 to $420. This action signals continued analyst confidence in the company's fundamentals and future performance. While the price target increase is relatively small, it reinforces a positive sentiment around ONC, potentially providing a minor boost to investor confidence. For traders, this could translate into short-term positive momentum, but the long-term implications depend more on the company's actual performance and pipeline developments rather than this incremental analyst update. The key opportunity for traders lies in recognizing this sustained positive analyst coverage as a potential floor for the stock price.

$ONC positive Analyst maintains Buy rating and raises price target
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.